Editas Medicine (EDIT) FCF Margin (2015 - 2025)

Editas Medicine (EDIT) has 11 years of FCF Margin data on file, last reported at 407.38% in Q3 2025.

• FCF Margin for Q3 2025 came in at 407.38%, up 9059098.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 369.52% (down 6595.0% YoY), and the FY2024 annual result was 650.95%, down 48068.0% from the prior year.
• FCF Margin improved to 407.38% in Q3 2025 per EDIT's latest filing, from 1403.35% in the prior quarter.
• Over five years, FCF Margin peaked at 32.76% in Q4 2023 and troughed at 122311.9% in Q3 2022.
• A 5-year average of 13120.33% and a median of 760.23% in 2022 frame the typical range for FCF Margin.
• The sharpest annual moves came in 2022 and 2023: FCF Margin sank 12166154 bps in 2022, then soared 12158741 bps in 2023.
• A 5-year view of FCF Margin shows it stood at 278.56% in 2021, then slumped by 136 bps to 656.32% in 2022, then soared by 95 bps to 32.76% in 2023, then tumbled by 324 bps to 139.0% in 2024, then sank by 193 bps to 407.38% in 2025.
• Business Quant data shows EDIT's FCF Margin at 407.38% in Q3 2025, 1403.35% in Q2 2025, and 1028.62% in Q1 2025.